POU2F3 and small cell lung carcinoma: Interestingly, these were not found with previously reported subtyping markers, including ASCL1, NEUROD1, and POU2F3, suggesting its role as a superior biomarker for NE-low SCLC patient stratification and warranting future validation with independent cohorts.